Author:
Procopio G.,Verzoni E.,Bracarda S.,Ricci S.,Sacco C.,Ridolfi L.,Porta C.,Miceli R.,Zilembo N.,Bajetta E.
Reference17 articles.
1. Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial;Procopio;Br J Cancer,2011
2. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial;Rini;Lancet,2011
3. Axitinib vs sorafenib for advanced renal cell carcinoma: phase III overall survival results and analysis of prognostic factors;Motzer;Ann Oncol,2012
4. Temsirolimus versus sorafenib as second-line therapy in patients with advanced rcc who have failed first-line sunitinib (INTORSECT);Hutson;Ann Oncol,2012
5. Overall survival results from a phase 3 study of tivozanib hydrochloride vs sorafenib in patients with renal cell carcinoma;Motzer;Pro ASCO GU,2013
Cited by
23 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献